108 Chapter 5 Total (N=6547) Awareb (N =3223) Not aware (N=2155) p Treated (N = 5966) Not treated (N = 581 p Controlleda (N=3038 Not controlled (p=3509) p Sex Male 4776 (72.9) 2331 (72.3) 1649 (76.5) <0.001 480 (82.6) 4296 (72.0) <0.001 2197 (72.3) 2579 (73.5) 0.297 Female 1771 (27.1) 892 (27.7) 506 (23.5) 101 (17.4) 1670 (28.0) 841 (27.7) 930 (26.5) Mean age (SD) 64.5 (9.21) 64.4 (9.13) 64.7 (9.35) 0.365 63.9 (9.68) 64.6 (9.16) 0.099 63.8 (9.30) 65.1 (9.08) <0.001 Education Primary or lower 913 (14.2) 307 (9.6) 416 (19.5) <0.001 115 (20.2) 798 (13.6) <0.001 364 (12.2) 549 (15.9) <0.001 Secondary 2749 (42.7) 1284 (40.1) 949 (44.6) 230 (40.4) 2519 (43.0) 1272 (42.6) 1477 (42.8) Tertiary 2769 (43.1) 1611 (50.3) 763 (35.9) 225 (39.5) 2544 (43.4) 1347 (45.2) 1422 (41.2) CHD diagnostic category CABG 477 (7.3) 258 (8.0) 142 (6.6) 0.003 60 (10.3) 417 (7.0) 0.03 198 (6.5) 279 (8.0) 0.003 PTCA 1725 (26.3) 878 (27.2) 546 (25.3) 134 (23.1) 1591 (26.7) 794 (26.1) 931 (26.5) STEMI 1653 (25.2) 823 (25.5) 555 (25.8) 147 (25.3) 1506 (25.2) 829 (27.3) 824 (23.5) NSTEMI 1323 (20.2) 591 (18.3) 481 (22.3) 119 (20.5) 1204 (20.2) 591 (19.5) 732 (20.9) UA/AMI 1369 (20.9) 673 (20.9) 431 (20.0) 121 (20.8) 1248 (20.9) 626 (20.6) 743 (21.2) Table 2. Characteristics of the EUROASPIRE V study population by hypertension awareness, treatment and control, in number of patients (%), unless indicated.
RkJQdWJsaXNoZXIy MTk4NDMw